Showing 161-170 of 381 results for "".
- Teledermoscopy Speeds Time to Case Resolution. In Australiahttps://practicaldermatology.com/news/teledermoscopy-speeds-time-to-case-resolution-in-australia/2457768/Teledermatology for skin cancer referral and triage would add to the costs of care but would result in more rapid clinical resolution&m
- Possible Eczema Breakthrough? S. aureus May Promote Skin Inflammation via IL-36-Mediated T Cell Responseshttps://practicaldermatology.com/news/possible-eczema-breakthrough-s-aureus-may-promotes-skin-inflammation-via-il-36-mediated-t-cell-responses/2457978/Toxin-producing bacteria on the surface of our skin may induce a protein that causes our own cells to react and cause inflammation, according to research published online in Cell Host & Microbe. <
- Billionaire John Paul DeJoria Bets Big on Aubío for Cold Sores and Maybe Morehttps://practicaldermatology.com/news/billionaire-john-paul-digorio-bets-on-aubo-for-cold-sores-and-maybe-more/2458461/Billionaire John Paul DiJoria of Paul Mitchell Professional Hair Care Products and Patron Tequila fame is putting his money where his mouth is --- literally. DeJoria is now investing “heavily” in a new natural and sustainably produced over-the-counter (OTC) col
- Brickell Secures Rights to a Novel Class of RORγ Inhibitors for Psoriasis and Other Autoimmune Diseaseshttps://practicaldermatology.com/news/brickell-biotech-secures-rights-to-a-novel-class-of-ror-inhibitors-for-psoriasis-and-other-autoimmune-diseases/2458801/Brickell Biotech, Inc. has secured the exclusive world-wide rights to a series of novel retinoic acid–related orphan nuclear receptor gamma (RORy) inhibitors from Orca Pharmaceuticals (Orca) and New York University (NYU). This chemical series is based on intellectual property emerg
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as
- Clinical Trials Designed to Block Autophagy in Multiple Cancers, Including Melanoma, Show Promisehttps://practicaldermatology.com/news/20140606-clinical_trials_designed_to_block_autophagy_in_multiple_cancers_including_melanoma_show_promise/2459217/
- Michelson Diagnostics Commences New Study with Melanoma Institute of Australiahttps://practicaldermatology.com/news/20140520-michelson_diagnostics_commences_new_study_with_melanoma_institute_of_australia/2459234/The UK based medical device company Michelson Diagnostics has commenced a clinical study to investigate use of Optical Coherence Tomography (OCT) in diagnosing basal cell carcinoma in collaboration with the Melanoma Institute of
- Study Finds Prevalence of Indoor Tanning Common in US, Europe, and Australiahttps://practicaldermatology.com/news/20140130-study_finds_prevalence_of_indoor_tanning_common_in_us_europe_and_australia/2459355/
- Study: 90% Would Purchase Red Light Therapy Deviceshttps://practicaldermatology.com/news/study-90-would-purchase-red-light-therapy-devices/2475498/New research published in the Journal of Clinical and Aesthetic Dermatology showed how social media is fueling the growing consumer demand for over-the-counter (OTC) red light therapy (RLT) devices. The authors of the
- AB Chopra Epigenetics Launches With Plan to Revolutionize Longevityhttps://practicaldermatology.com/news/AB-Chopra-Epigenetics-Launches-With-Plan-Revolutionize-Longevity/2475124/Charles Rosier, co-founder of the Augustinus Bader skincare and biotech company, and Deepak Chopra, MD, announced the launch of AB Chopra Epigenetics, a revolutionary longevity platform that merges advanced artificial intelligence, epigenetic science, and consciousness-based healing to redefine t